BIOQUAL, Inc.

As of August 31, 2011, BIOQUAL, Inc. carries a market capitalization of 5.56M, placing it among publicly traded companies globally. Its enterprise value stands at 1.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of August 31, 2011, BIOQUAL, Inc. has 896,000.00 shares outstanding.

As of August 31, 2011, BIOQUAL, Inc. trades at a trailing price-to-earnings ratio of 8.15. The price-to-sales ratio is 0.23, and the price-to-book ratio stands at 0.52.

As of August 31, 2011, BIOQUAL, Inc. trades at an EV/EBITDA multiple of 0.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BIOQUAL, Inc. trades at an EV/FCF ratio of 0.87, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.80M versus a market cap of 5.56M, with the gap driven by net debt and cash on the balance sheet.

As of August 31, 2011, BIOQUAL, Inc. maintains a current ratio of 3.75, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended August 31, 2011. The company generates approximately 204,216.63 in revenue per employee across its workforce of 117.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended August 31, 2011, BIOQUAL, Inc. recorded 479,142.00 in income tax expense. That works out to an effective tax rate of 41.23, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.16M, leaving 683,897.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, BIOQUAL, Inc.'s stock has declined approximately 23.40% over the past 52 weeks. The 50-day moving average sits at 52.86, while the 200-day moving average is 72.77.

Over the twelve months ended August 31, 2011, BIOQUAL, Inc. generated 23.89M in revenue and converted that into 683,897.00 in net income, yielding earnings per share of 0.76. EBITDA reached 1.97M, while operating income came in at 1.16M.

These figures are as of August 31, 2011. Total book value stands at 10.64M, with working capital of 7.97M providing operational flexibility.

BIOQUAL, Inc. produced 2.06M in operating cash flow over the twelve months ended August 31, 2011.

Over the twelve months ended August 31, 2011, BIOQUAL, Inc. posted a gross margin of 21.21, reflecting its pricing power and cost economics. The operating margin of 4.85 and net profit margin of 2.86 provide insight into operational efficiency.

Over the twelve months ended August 31, 2011, BIOQUAL, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 36.92, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.46, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BIOQUAL, Inc. shareholders.

BIOQUAL, Inc.'s most recent stock split took place on October 30, 1997 with a 6:1 split ratio.

As of August 31, 2011, BIOQUAL, Inc. has an Altman Z-Score of 4.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.